Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity

Abstract

A dose of bevacizumab as low as 0.031 mg was effective in 9 of 9 eyes in this phase 1 study and warrants further investigation. Identifying a lower effective dose of bevacizumab may reduce the risk for neurodevelopmental disability or detrimental effects on other organs.